infection intravascularly etc inhaled treatments are of particular interest depending upon the manner of introduction the compounds may be formulated in a variety of ways the concentration of therapeutically active compound in the formulation may vary from about 1 0 100 wt the pharmaceutical compositions can be prepared in various forms such as granules tablets pills suppositories capsules suspensions salves lotions and the like pharmaceutical grade organic or inorganic carriers and or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically active compounds diluents known to the art include aqueous media vegetable and animal oils and fats stabilizing agents wetting and emulsifying agents salts for varying the osmotic pressure or buffers for securing an adequate ph value and skin penetration enhancers can be used as auxiliary agents the following examples relate to pathophysiological characteristics of a transgenic mouse tolerant to human iduronate 2 sulfatase without generating anti ids igg antibody compared to that of a wild type mouse the urine amount of glycosaminoglycan gag in a 38 weeks old transgenic mouse was in the range of 135 175 u03bcg ml on the other hand the urine amount of gag in a 38 weeks old wild type mouse was in the range of 10 30 u03bcg ml therefore the urine amount of gag of the 38 weeks old transgenic mouse was.